Join
Live feed
·
PRReleasevia Quantisnow
Zentalis Pharmaceuticals Inc. logo

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

ByQuantisnow·Wall Street's wire, on your screen.
ZNTL· Zentalis Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZNTL (Zentalis Pharmaceuticals Inc.) and more on Quantisnow.